VectiveBio: Positive interim Phase 2 data in intestinal failure trial

  Treatment with apraglutide resulted in an average 50% reduction in Parenteral Support (PS) volume at six months

•  80% of patients were clinical responders (defined as a reduction in volume of PS of at least 20%) and achieved at least one day off PS at six months

•  First study to prospectively show evidence of clinical benefit in SBS-IF Patients with Colon-in-Continuity after treatment with a GLP-2 Agonist

•  CIC patients represent largest unmet need in SBS-IF

https://finance.yahoo.com/news/vectivbio-reports-positive-interim-clinical-110000727.html